Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy.

Authors :: de Rooij, Martin F. M.
Kuil, Annemieke
Kater, Arnon P.
Kersten, Marie José
Pals, Steven T.
Spaargaren, Marcel
Source :: Blood. 04/02/2015, Vol. 125 Issue 14, p2306-2308. 3p.
Publication Year :: 2015
Abstract: A letter to the editor is presented regarding a rationale for combination therapy of ibrutinib and idelalisib in B-cell receptor (BCR)-controlled adhesion in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) .

Full Text Access

Tools